Alpha Cognition Inc. is a biopharmaceutical company developing treatments for neurodegenerative diseases, with a focus on Alzheimer's disease. The company's lead product is an FDA-approved next-generation acetylcholinesterase inhibitor featuring an enteric-coated formulation designed to minimize gastrointestinal side effects while enhancing cognition through neuronal nicotinic receptor binding. Alpha Cognition generates revenue through direct product sales to healthcare providers and payors, employing a specialized commercialization strategy targeting long-term care facilities where the majority of acetylcholinesterase inhibitor prescriptions occur, and pursues international expansion through licensing agreements while maintaining a pipeline of combination and alternative-formulation compounds for various cognitive disorders.